mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants

in: bioRxiv.org | 2024

by Wu, K. | Werner, A. | Moliva, J. | +11

SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness

in: bioRxiv.org | 2024

by Corbett, K. | Edwards, D. | Leist, S. | +56

A Platform Incorporating Trimeric Antigens into Self-Assembling Nanoparticles Reveals SARS-CoV-2-Spike Nanoparticles to Elicit Substantially Higher Neutralizing Responses than Spike Alone

in: bioRxiv.org | 2024

by Zhang, B. | Chao, C. | Tsybovsky, Y. | +19

Protective Antibodies Against Human Parainfluenza Virus Type 3 (HPIV3) Infection

in: bioRxiv.org | 2024

by Boonyaratanakornkit, J. | Singh, S. | Weidle, C. | +8

Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques

in: bioRxiv.org | 2024

by Williams, W. | Meyerhoff, R. | Edwards, R. | +40

Potently neutralizing human monoclonal antibodies against the zoonotic pararubulavirus Sosuga virus

in: bioRxiv.org | 2024

by Parrington, H. | Kose, N. | Armstrong, E. | +10

A monkeypox mRNA-lipid nanoparticle vaccine targeting virus binding, entry, and transmission drives protection against lethal orthopoxviral challenge

in: bioRxiv.org | 2023

by Freyn, A. | Atyeo, C. | Earl, P. | +20

Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice

in: bioRxiv.org | 2022

by Wu, K. | Choi, A. | Koch, M. | +22

mRNA-1273 efficacy in a severe COVID-19 model: attenuated activation of pulmonary immune cells after challenge

in: bioRxiv.org | 2022

by Meyer, M. | Wang, Y. | Edwards, D. | +25

Development of SARS-CoV-2 mRNA vaccines encoding spike N-terminal and receptor binding domains

in: bioRxiv.org | 2022

by Stewart-Jones, G. | Elbashir, S. | Wu, K. | +22